Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
Gotlib J.
Am J Hematol. 2012 Sep;87(9):903-14. doi: 10.1002/ajh.23293.
Related citations
Complete response of myeloid sarcoma with FIP1L1-PDGFRA -associated myeloproliferative neoplasms to imatinib mesylate monotherapy.
Tang TC, Chang H, Chuang WY.
Acta Haematol. 2012;128(2):83-7. doi: 10.1159/000338217. Epub 2012 Jun 19.
Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.
Arefi M, García JL, Peñarrubia MJ, Queizán JA, Hermosín L, López-Corral L, Megido M, Giraldo P, de las Heras N, Vanegas RJ, Gutiérrez NC, Hernández-Rivas JM.
Eur J Haematol. 2012 Jul;89(1):37-41. doi: 10.1111/j.1600-0609.2012.01799.x.
Congenital and childhood myeloproliferative disorders with eosinophilia responsive to imatinib.
Abraham S, Salama M, Hancock J, Jacobsen J, Fluchel M.
Pediatr Blood Cancer. 2012 Nov;59(5):928-9. doi: 10.1002/pbc.24148. Epub 2012 Apr 5.
Eosinophilic myeloid disorders.
Noel P.
Semin Hematol. 2012 Apr;49(2):120-7. doi: 10.1053/j.seminhematol.2012.01.008. Review.
Molecular alterations underlying eosinophilic and mast cell malignancies.
Sadrzadeh H, Abdel-Wahab O, Fathi AT.
Discov Med. 2011 Dec;12(67):481-93. Review.
The myeloproliferative neoplasms including the eosinophilia-related myeloproliferations associated with tyrosine kinase mutations: changes and issues in classification and diagnosis criteria.
Anastasi J.
Semin Diagn Pathol. 2011 Nov;28(4):304-13. Review.
World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants.
Vardiman J, Hyjek E.
Hematology Am Soc Hematol Educ Program. 2011;2011:250-6. doi: 10.1182/asheducation-2011.1.250. Review.
Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm.
Chmielecki J, Peifer M, Viale A, Hutchinson K, Giltnane J, Socci ND, Hollis CJ, Dean RS, Yenamandra A, Jagasia M, Kim AS, Davé UP, Thomas RK, Pao W.
Genes Chromosomes Cancer. 2012 Jan;51(1):54-65. doi: 10.1002/gcc.20930. Epub 2011 Sep 21.
Application of tyrosine kinase inhibitors as a promising targeting treatment for myeloproliferative neoplasms --- review.
Wei M, Gao CJ.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Aug;19(4):1064-70. Review.
World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
Am J Hematol. 2011 Aug;86(8):677-88. doi: 10.1002/ajh.22062. Review.
Quantification of PDGFRA alternative transcripts improves the screening for X-PDGFRA fusions by reverse transcriptase-polymerase chain reaction.
Erquiaga I, Ormazábal C, Hurtado C, Aranaz P, Calasanz MJ, García-Delgado M, Novo FJ, Vizmanos JL.
Leuk Lymphoma. 2010 Sep;51(9):1720-6. doi: 10.3109/10428194.2010.497575.
Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
Rathe M, Kristensen TK, Møller MB, Carlsen NL.
Pediatr Blood Cancer. 2010 Oct;55(4):730-2. doi: 10.1002/pbc.22655.
FIP1L1/PDGFR alpha-associated systemic mastocytosis.
Yamada Y, Cancelas JA.
Int Arch Allergy Immunol. 2010;152 Suppl 1:101-5. doi: 10.1159/000312134. Epub 2010 Jun 4. Review.
Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1.
Bain BJ.
Haematologica. 2010 May;95(5):696-8. doi: 10.3324/haematol.2009.021675. No abstract available.
Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.
Wadleigh M, Tefferi A.
Int J Hematol. 2010 Mar;91(2):174-9. doi: 10.1007/s12185-010-0529-5. Epub 2010 Feb 27. Review.
Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis.
Erben P, Gosenca D, Müller MC, Reinhard J, Score J, Del Valle F, Walz C, Mix J, Metzgeroth G, Ernst T, Haferlach C, Cross NC, Hochhaus A, Reiter A.
Haematologica. 2010 May;95(5):738-44. doi: 10.3324/haematol.2009.016345. Epub 2010 Jan 27.
Eosinophilic myeloid disorders: new classification and novel therapeutic strategies.
Curr Opin Hematol. 2010 Mar;17(2):117-24. doi: 10.1097/MOH.0b013e3283366c70. Review.
The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms.
Vardiman JW.
Chem Biol Interact. 2010 Mar 19;184(1-2):16-20. doi: 10.1016/j.cbi.2009.10.009. Epub 2009 Oct 24. Review.
Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
Lierman E, Cools J.
Expert Rev Anticancer Ther. 2009 Sep;9(9):1295-304. doi: 10.1586/era.09.82. Review.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on